Where can I find news about GH?

The latest headlines, third-party analysis, and SEC filings for Guardant Health, Inc. (GH) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are GH's SEC filings?

Guardant Health, Inc. (GH)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are GH's earnings call transcripts?

Full earnings call transcripts for Guardant Health, Inc. (GH) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Guardant Health, Inc.

NASDAQ·Medical, Diagnostics & Research · Healthcare

$164.27$2.86+1.77%

Market cap$22.04B·Sep 8 3:59 PM UTC

News & Analysis

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations before radiographic progression who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-gener.
businesswire.comSep 4, 2026 · 6:10 PM
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
benzinga.comSep 1, 2026 · 12:25 PM
Guardant Health's Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty benefits managers in the country and subsidiary of one of the largest health insurance companies in the U.S spanning more than 14 states. The new policy update fr.
businesswire.comSep 1, 2026 · 8:05 AM
Why Rule Breakers Buy a Stock That's Already "Won"
You found a great company, then watched it double before you got round to buying.
fool.comAug 31, 2026 · 3:37 PM
Bamco Inc. NY Makes New $2.48 Million Investment in Guardant Health, Inc. $GH
Bamco Inc. NY bought a new stake in Guardant Health, Inc. (NASDAQ: GH) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 16,500 shares of the company's stock, valued at approximately $2,475,000. A number of other institutional investors have also modified their holdings
defenseworld.netAug 28, 2026 · 3:53 AM
Callan Family Office LLC Invests $912,000 in Guardant Health, Inc. $GH
Callan Family Office LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,080 shares of the company's stock, valued at approximately $912,000. A number of other institutional investors and
defenseworld.netAug 25, 2026 · 6:01 AM
Guardant Health Inc (GH) Shares Fall 4.4% -- What GF Score of 65 Tells Investors
On August 24, 2026, Guardant Health Inc (GH) shares fell 4.4% to a current price of $163.18, reflecting a volatile trading environment. The stock has experience
gurufocus.comAug 24, 2026 · 5:53 PM
Guardant Health to Appeal Federal District Court Judgment
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the
gurufocus.comAug 24, 2026 · 3:00 PM

SEC Filings

SC 13G/A
Aug 14, 2026View on SEC
S-3ASR
Jul 30, 2026View on SEC
10-Q
Jul 30, 2026View on SEC
8-K
Jul 30, 2026View on SEC
SC 13G/A
Jul 28, 2026View on SEC
8-K
Jun 18, 2026View on SEC

Frequently Asked Questions About GH

Where can I find news about GH?: The latest headlines, third-party analysis, and SEC filings for Guardant Health, Inc. (GH) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are GH's SEC filings?: Guardant Health, Inc. (GH)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are GH's earnings call transcripts?: Full earnings call transcripts for Guardant Health, Inc. (GH) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Guardant Health, Inc.

Frequently Asked Questions About GH

Guardant Health, Inc.

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Guardant Health's Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

Why Rule Breakers Buy a Stock That's Already "Won"

Bamco Inc. NY Makes New $2.48 Million Investment in Guardant Health, Inc. $GH

Callan Family Office LLC Invests $912,000 in Guardant Health, Inc. $GH